肿瘤免疫组合疗法Opdivo/NKTR-214开展5种肿瘤治疗研究

2016-09-29 佚名 生物谷

肿瘤免疫治疗领域的绝对领跑者百时美施贵宝(BMS)近日宣布与Nektar制药公司达成一项新的临床合作,评估百时美的PD-1免疫疗法Opdivo(nivolumab)与Nektar公司的免疫刺激疗法NKTR-214的组合方案,用于5种肿瘤类型及潜在7个适应症。 Opdivo是一种PD-1免疫检查点抑制剂,旨在克服免疫抑制;NKTR-214则是一种免疫刺激疗法,旨在直接扩张肿瘤微环境中的特异性抗

肿瘤免疫治疗领域的绝对领跑者百时美施贵宝(BMS)近日宣布与Nektar制药公司达成一项新的临床合作,评估百时美的PD-1免疫疗法Opdivo(nivolumab)与Nektar公司的免疫刺激疗法NKTR-214的组合方案,用于5种肿瘤类型及潜在7个适应症。

Opdivo是一种PD-1免疫检查点抑制剂,旨在克服免疫抑制;NKTR-214则是一种免疫刺激疗法,旨在直接扩张肿瘤微环境中的特异性抗癌T细胞和自然杀死细胞(NK),同时增加这些免疫细胞表面PD-1的表达水平。Opdivo与NKTR-214具有2种不同的、互补性的作用机制;将2者联合用药有望提高机体免疫系统对抗癌症的能力。

根据协议,双方将开展一项I/II期临床研究,评估Opdivo+NKTR-214组合疗法用于5种类型肿瘤(黑色素瘤、肾细胞癌、结直肠癌、膀胱癌、非小细胞肺癌),并与当前标准护理疗法进行对比。目前,一项初步的剂量递增试验正在进行中。百时美和Nektar将平摊临床开发成本,Nektar将保留NKTR-214的全球商业化权利。

NKTR-214能够增加体内肿瘤浸润性淋巴细胞(TILs)数量来补充免疫系统,这一点至关重要,因为许多患者因体内缺乏足够的TILs细胞群,导致难以从目前已获批的免疫检查点抑制剂中受益。将免疫检查点抑制剂联合T细胞增殖可能会产生协同作用,从而为患者提供一个新的治疗选择。

Opdivo是全球获批的首个PD-1免疫检查点抑制剂,于2014年7月获批上市,目前已在美国、日本、欧盟等54个国家获批上市。

NKTR-214是一种实验性药物,旨在靶向存在于CD8+效应T细胞和自然杀死细胞(NK cell)表面的CD122特异性受体,刺激体内的这些抗癌免疫细胞。在临床前研究中,NKTR-214治疗导致这些细胞快速扩张并动员到肿瘤微环境中去。NKTR-214具有抗体类药物的给药方式,与目前已获批的免疫检查点抑制剂药物给药方式相似。目前,Nektar公司正在开展一项I/II期研究,评估NKTR-214单药疗法治疗多种肿瘤的潜力。

原始出处:

Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773057, encodeId=c6721e73057e4, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Thu Mar 09 02:05:00 CST 2017, time=2017-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929143, encodeId=c4e11929143c8, content=<a href='/topic/show?id=d25f12846e6' target=_blank style='color:#2F92EE;'>#NKTR-214#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12846, encryptionId=d25f12846e6, topicName=NKTR-214)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Nov 02 17:05:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751729, encodeId=c2541e5172934, content=<a href='/topic/show?id=ba8612842b3' target=_blank style='color:#2F92EE;'>#NKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12842, encryptionId=ba8612842b3, topicName=NKT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74e936405699, createdName=xuruicheng, createdTime=Tue Jun 06 00:05:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143116, encodeId=fe6714311619, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:48 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303052, encodeId=304713030523e, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Oct 01 10:05:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304031, encodeId=081a1304031ad, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat Oct 01 10:05:00 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773057, encodeId=c6721e73057e4, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Thu Mar 09 02:05:00 CST 2017, time=2017-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929143, encodeId=c4e11929143c8, content=<a href='/topic/show?id=d25f12846e6' target=_blank style='color:#2F92EE;'>#NKTR-214#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12846, encryptionId=d25f12846e6, topicName=NKTR-214)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Nov 02 17:05:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751729, encodeId=c2541e5172934, content=<a href='/topic/show?id=ba8612842b3' target=_blank style='color:#2F92EE;'>#NKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12842, encryptionId=ba8612842b3, topicName=NKT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74e936405699, createdName=xuruicheng, createdTime=Tue Jun 06 00:05:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143116, encodeId=fe6714311619, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:48 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303052, encodeId=304713030523e, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Oct 01 10:05:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304031, encodeId=081a1304031ad, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat Oct 01 10:05:00 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
    2016-11-02 zhouqu_8
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773057, encodeId=c6721e73057e4, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Thu Mar 09 02:05:00 CST 2017, time=2017-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929143, encodeId=c4e11929143c8, content=<a href='/topic/show?id=d25f12846e6' target=_blank style='color:#2F92EE;'>#NKTR-214#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12846, encryptionId=d25f12846e6, topicName=NKTR-214)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Nov 02 17:05:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751729, encodeId=c2541e5172934, content=<a href='/topic/show?id=ba8612842b3' target=_blank style='color:#2F92EE;'>#NKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12842, encryptionId=ba8612842b3, topicName=NKT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74e936405699, createdName=xuruicheng, createdTime=Tue Jun 06 00:05:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143116, encodeId=fe6714311619, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:48 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303052, encodeId=304713030523e, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Oct 01 10:05:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304031, encodeId=081a1304031ad, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat Oct 01 10:05:00 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
    2017-06-06 xuruicheng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1773057, encodeId=c6721e73057e4, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Thu Mar 09 02:05:00 CST 2017, time=2017-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929143, encodeId=c4e11929143c8, content=<a href='/topic/show?id=d25f12846e6' target=_blank style='color:#2F92EE;'>#NKTR-214#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12846, encryptionId=d25f12846e6, topicName=NKTR-214)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Nov 02 17:05:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751729, encodeId=c2541e5172934, content=<a href='/topic/show?id=ba8612842b3' target=_blank style='color:#2F92EE;'>#NKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12842, encryptionId=ba8612842b3, topicName=NKT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74e936405699, createdName=xuruicheng, createdTime=Tue Jun 06 00:05:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143116, encodeId=fe6714311619, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:48 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303052, encodeId=304713030523e, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Oct 01 10:05:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304031, encodeId=081a1304031ad, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat Oct 01 10:05:00 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
    2016-10-10 1e10c84am36(暂无匿称)

    文章很好,继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1773057, encodeId=c6721e73057e4, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Thu Mar 09 02:05:00 CST 2017, time=2017-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929143, encodeId=c4e11929143c8, content=<a href='/topic/show?id=d25f12846e6' target=_blank style='color:#2F92EE;'>#NKTR-214#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12846, encryptionId=d25f12846e6, topicName=NKTR-214)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Nov 02 17:05:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751729, encodeId=c2541e5172934, content=<a href='/topic/show?id=ba8612842b3' target=_blank style='color:#2F92EE;'>#NKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12842, encryptionId=ba8612842b3, topicName=NKT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74e936405699, createdName=xuruicheng, createdTime=Tue Jun 06 00:05:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143116, encodeId=fe6714311619, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:48 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303052, encodeId=304713030523e, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Oct 01 10:05:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304031, encodeId=081a1304031ad, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat Oct 01 10:05:00 CST 2016, time=2016-10-01, status=1, ipAttribution=)]
    2016-10-01 119337457
  6. [GetPortalCommentsPageByObjectIdResponse(id=1773057, encodeId=c6721e73057e4, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Thu Mar 09 02:05:00 CST 2017, time=2017-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929143, encodeId=c4e11929143c8, content=<a href='/topic/show?id=d25f12846e6' target=_blank style='color:#2F92EE;'>#NKTR-214#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12846, encryptionId=d25f12846e6, topicName=NKTR-214)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Nov 02 17:05:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751729, encodeId=c2541e5172934, content=<a href='/topic/show?id=ba8612842b3' target=_blank style='color:#2F92EE;'>#NKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12842, encryptionId=ba8612842b3, topicName=NKT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74e936405699, createdName=xuruicheng, createdTime=Tue Jun 06 00:05:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143116, encodeId=fe6714311619, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:48 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303052, encodeId=304713030523e, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Oct 01 10:05:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304031, encodeId=081a1304031ad, content=<a href='/topic/show?id=c5558298426' target=_blank style='color:#2F92EE;'>#肿瘤治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82984, encryptionId=c5558298426, topicName=肿瘤治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat Oct 01 10:05:00 CST 2016, time=2016-10-01, status=1, ipAttribution=)]

相关资讯

NEJM:晚期黑色素瘤会抵抗PD-1 阻断治疗

近日,加州大学洛杉矶分校研究人员发现一种机制,该机制确定了晚期黑色素瘤是如何对免疫检查点抑制剂进行抵抗的,这一发现可能会引起设计新型治疗方案来治疗致命的皮肤癌。“免疫疗法可让我们身体的免疫防御系统抵抗癌症侵袭,但抵抗癌症必须是长期且持续的。”加州大学洛杉矶分校血液学和肿瘤学教授Ribas说。“我们首次了解了肿瘤细胞可以避免被免疫系统T细胞识别,这样就降低了免疫系统对肿瘤细胞攻击的敏感性。”研究人员

JAMA Oncol:不同肿瘤和治疗方案下,PD-1抑制剂相关肺炎发生情况如何?

程序性细胞死亡1 (PD-1)抑制剂相关肺炎是一种罕见但严重、具有潜在生命威胁的不良事件。而目前不同肿瘤类型和治疗方案间的发生率是鲜为人知的。我们进行了研究,比较不同肿瘤类型和治疗方案间,PD-1抑制剂相关肺炎的发生率。 通过检索相关数据库,发现了26篇报告PD-1抑制剂相关肺炎的文献,纳入了20篇(共涉及4496例患者)关于黑色素瘤(n=12)、非小细胞肺癌(NSCLC;n=5)或肾细胞癌

PNAS: PD-1对于调节性T细胞中介导免疫耐受中的作用

外周免疫耐受受到多种机制的调节,以T细胞为例:激活引发的细胞凋亡,克隆失活,负向共刺激因子以及Treg细胞介导的免疫抑制等等共同抑制了T细胞的过度激活。大部分的调节信号都有一定的冗余,比如共刺激因子CTLA-4与和转录因子FoxP3,两者均能够调节其它T细胞的活性。FoxP3是Treg细胞的标志,它能够调节一百多个靶基因的表达,其中FoxP3能够直接促进CTLA4的表达,而后者则能够通过竞争性地与

J immunol:病毒感染中多重抑制性信号阻断CD8 T细胞活性

呼吸道病毒,尤其是偏肺病毒,是造成下呼吸道感染的主要原因,而且会引起极高的发病率与致死率。在医院中,会受到偏肺病毒二次感染的患者大多为哮喘、慢性呼吸系统紊乱、艾滋病以及早产等等。在CD8 T细胞不足的人群中,HPMV的感染会引发严重甚至致死的疾病,这说明CD8 T细胞对于病毒的清除具有重要的作用。另外,T细胞介导的炎症反应对于其它类型呼吸道病毒感染后引发的肺部损伤等疾病也有一定的影响。 此前对

JCO:Nivolumab可安全有效的治疗复发性/难治性血液恶性肿瘤

通过调节T细胞活性,癌细胞可以利用程序性死亡-1(PD-1)免疫检查点通路来逃避免疫监视。部分上是通过PD-1和PD-1通路配体(PD-L1 和 PD-L2)的过表达来实现。实体瘤中,阻断PD-1可产生显著的抗肿瘤活性,血液肿瘤中也有类似的研究发现。 在此1阶段、开放性、剂量递增、队列扩展研究中,纳入了复发性/难治性B细胞淋巴瘤、T细胞淋巴瘤和多发性骨髓瘤患者,所有患者每2周接受13 mg/

NEJM:黑色素瘤患者PD-1免疫疗法耐药性的机制被揭示

黑色瘤患者接受抗程序性死亡1(PD-1)治疗时的客观反应率约为75%,耐受性良好,效果可持续数年,但是首次用药后仍会出现延迟复发,尽管此时仍在使用抗PD-1治疗。而这种免疫逃避机制尚未可知。研究人员分析了4名转移性黑色素瘤患者基线及复发病损区域的活组织检查样本。这4名患者初次接受抗PD-1治疗(pembrolizumab)后肿瘤消退,但是日后肿瘤复发数月至数年。测定获得性耐药肿瘤细胞的全基因组序列